Journal
FUTURE ONCOLOGY
Volume 11, Issue 4, Pages 703-712Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon.14.281
Keywords
basal cell carcinoma; locally advanced basal cell carcinoma; therapy; vismodegib
Categories
Funding
- Roche
- Eisai
- Merck Serono
- Amgen
- Boehringer Ingelheim
- BMS
Ask authors/readers for more resources
Basal cell carcinoma (BCC) is the most common skin cancer worldwide. Most occur on the head and neck, where cosmetic and functional outcomes are critical. BCC can be locally destructive if not diagnosed early and treated appropriately. Surgery is the treatment of choice for the majority of high-risk lesions. Aggressive, recurrent or unresectable tumors can be difficult to manage. Until recently, no approved systemic therapy was available for locally advanced or metastatic BCC inappropriate for surgery or radiotherapy. Vismodegib provides a systemic treatment option. However, a consensus definition of advanced BCC is lacking. A multidisciplinary panel with expertise in oncology, dermatology, dermatologic surgery and radiation oncology proposes a consensus definition based on published evidence and clinical experience.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available